ArticleFrontiers in medicine2026
XGBoost outperforms other machine learning models in diagnosing Sepsis-Associated Thrombocytopenia: a multicenter retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sepsis-associated thrombocytopenia is a frequent complication of sepsis and is associated with poor clinical outcomes. Accurate diagnosis remains challenging, and machine learning approaches may offer improved diagnostic performance. The objective of this study was to conduct a comparative assessment of the performance of machine learning models (Random Forest, Artificial Neural Networks, Extreme Gradient Boosting, and Naive Bayes) in diagnosing sepsis-associated thrombocytopenia and to evaluate their diagnostic performance based on predefined performance criteria. Methods: This retrospective cross-sectional study was conducted at two centers and utilized data from 1,447 sepsis patients extracted from electronic health records between January 2013 and December 2023. The dataset comprised demographic and clinical attributes together with laboratory test results. The data were partitioned into training and test sets in an 80:20 ratio. All models were trained on the training set, and 10-fold cross-validation was applied within the training set to assess internal performance consistency. Model performance was evaluated using accuracy, precision, F1 score, AUROC, and confusion matrix. The ten most significant variables were ranked using classifier-based feature importance and SHAP analysis. Results: Thrombocytopenia occurred in 772 (53.4%) of the 1,447 sepsis patients. Cross-validation results indicated that XGBoost exhibited superior performance, achieving an accuracy of 91.10% and an F1 score of 92.31%. ANN and RF achieved accuracies of 90.32% and 83.75%, with F1 scores of 91.51% and 85.32%, respectively. The AUROC values for cross-validation and test sets of RF, ANN, XGBoost, and Naive Bayes models exceeded 90%. Conclusion: Among the evaluated algorithms, the XGBoost model demonstrated superior performance, achieving an AUROC of 98.60% in cross-validation and 97.50% in the test set, indicating the strongest performance metrics within internal validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.